Intranasal Delivery of Insulin Therapeutics for Alzheimer’s Disease
Published in Zenodo, 2025
Abstract
Alzheimer’s disease (AD) represents one of the most pressing challenges in modern neuroscience and clinical medicine. This review examines the emerging therapeutic approach of intranasal insulin delivery for Alzheimer’s disease treatment, exploring the mechanistic rationale, clinical evidence, and biomedical engineering considerations that make this route of administration particularly promising for neurodegenerative disease intervention.
Intranasal delivery bypasses the blood-brain barrier through direct nose-to-brain transport pathways, enabling targeted central nervous system drug delivery while minimizing systemic exposure and side effects. The review synthesizes current understanding of insulin’s neuroprotective mechanisms in the brain, including its roles in glucose metabolism, synaptic plasticity, amyloid-beta clearance, and tau protein regulation—all critical factors in Alzheimer’s disease pathology.
Publication Details
Published: November 12, 2025
Publication Type: Review Article
Publisher: Zenodo
DOI: 10.5281/zenodo.17591947
License: Creative Commons Attribution 4.0 International
Language: English
Keywords: Alzheimer Disease, Administration Intranasal, Biomedical Engineering, Medical Engineering
Citation
```bibtex @article{https://doi.org/10.5281/zenodo.17591947, doi = {10.5281/ZENODO.17591947}, url = {https://zenodo.org/doi/10.5281/zenodo.17591947}, author = {CHENG, Wan Kiu Winkey}, keywords = {Alzheimer Disease, Administration, Intranasal, Biomedical Engineering, FOS: Medical engineering}, language = {en}, title = {Intranasal Delivery of Insulin Therapeutics for Alzheimer’s Disease}, publisher = {Zenodo}, year = {2025}, copyright = {Creative Commons Attribution 4.0 International} }
Recommended citation: CHENG, Wan Kiu Winkey. (2025). "Intranasal Delivery of Insulin Therapeutics for Alzheimer Disease." Zenodo. https://doi.org/10.5281/zenodo.17591947
Download Paper